Saramäki OR - Search Results

1

CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.

Khanna A, Rane JK, Kivinummi KK, Urbanucci A, Helenius MA, Tolonen TT, Saramäki OR, Latonen L, Manni V, Pimanda JE, Maitland NJ, Westermarck J, Visakorpi T. Khanna A, et al. Among authors: saramaki or. Oncotarget. 2015 Aug 14;6(23):19661-70. doi: 10.18632/oncotarget.3875. Oncotarget. 2015. PMID: 25965834 Free PMC article.

2

Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.

Annala M, Kivinummi K, Tuominen J, Karakurt S, Granberg K, Latonen L, Ylipää A, Sjöblom L, Ruusuvuori P, Saramäki O, Kaukoniemi KM, Yli-Harja O, Vessella RL, Tammela TL, Zhang W, Visakorpi T, Nykter M. Annala M, et al. Oncotarget. 2015 Mar 20;6(8):6235-50. doi: 10.18632/oncotarget.3359. Oncotarget. 2015. PMID: 25749039 Free PMC article.

3

Amplification and overexpression of Elongin C gene discovered in prostate cancer by cDNA microarrays.

Porkka K, Saramäki O, Tanner M, Visakorpi T. Porkka K, et al. Lab Invest. 2002 May;82(5):629-37. doi: 10.1038/labinvest.3780457. Lab Invest. 2002. PMID: 12004003 Free article.

4

Chromosomal aberrations in prostate cancer.

Saramaki O, Visakorpi T. Saramaki O, et al. Front Biosci. 2007 May 1;12:3287-301. doi: 10.2741/2312. Front Biosci. 2007. PMID: 17485299

5

Copy number increase of oncoprotein CIP2A is associated with poor patient survival in human head and neck squamous cell carcinoma.

Routila J, Bilgen T, Saramäki O, Grénman R, Visakorpi T, Westermarck J, Ventelä S. Routila J, et al. J Oral Pathol Med. 2016 May;45(5):329-37. doi: 10.1111/jop.12372. Epub 2015 Oct 5. J Oral Pathol Med. 2016. PMID: 26436875

6

Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.

Sjöblom L, Saramäki O, Annala M, Leinonen K, Nättinen J, Tolonen T, Wahlfors T, Nykter M, Bova GS, Schleutker J, Tammela TL, Lilja H, Visakorpi T. Sjöblom L, et al. PLoS One. 2016 Mar 3;11(3):e0150241. doi: 10.1371/journal.pone.0150241. eCollection 2016. PLoS One. 2016. PMID: 26939004 Free PMC article.

7

Clusterin is epigenetically regulated in prostate cancer.

Rauhala HE, Porkka KP, Saramäki OR, Tammela TL, Visakorpi T. Rauhala HE, et al. Among authors: saramaki or. Int J Cancer. 2008 Oct 1;123(7):1601-9. doi: 10.1002/ijc.23658. Int J Cancer. 2008. PMID: 18649357 Free article.

8

Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer.

Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramäki OR, Visakorpi T. Leinonen KA, et al. Among authors: saramaki or. Clin Cancer Res. 2010 May 15;16(10):2845-51. doi: 10.1158/1078-0432.CCR-09-2505. Epub 2010 May 4. Clin Cancer Res. 2010. PMID: 20442300

9

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.

Leinonen KA, Saramäki OR, Furusato B, Kimura T, Takahashi H, Egawa S, Suzuki H, Keiger K, Ho Hahm S, Isaacs WB, Tolonen TT, Stenman UH, Tammela TL, Nykter M, Bova GS, Visakorpi T. Leinonen KA, et al. Among authors: saramaki or. Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2333-44. doi: 10.1158/1055-9965.EPI-13-0333-T. Epub 2013 Oct 1. Cancer Epidemiol Biomarkers Prev. 2013. PMID: 24083995 Free PMC article.

10

Amplification of the 9p13.3 chromosomal region in prostate cancer.

Latonen L, Leinonen KA, Grönlund T, Vessella RL, Tammela TL, Saramäki OR, Visakorpi T. Latonen L, et al. Among authors: saramaki or. Genes Chromosomes Cancer. 2016 Aug;55(8):617-25. doi: 10.1002/gcc.22364. Epub 2016 May 2. Genes Chromosomes Cancer. 2016. PMID: 27074291

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

95 results

Search Page